RÉSUMÉ
Aquagenic urticaria, a rare variant of chronic-inducible urticaria, is triggered by direct contact with water. It is distinguished by its characteristic small wheals accompanied by a halo of erythema from other forms of urticaria. It typically manifests with a delayed diagnosis due to the atypical trigger and the potential for diverse clinical presentations. We present a case of aquagenic urticaria in an adolescent male that demonstrates the need for accurate differential diagnosis and appropriate management.
Sujet(s)
Urticaire chronique inductible , Urticaire , Eau , Humains , Mâle , Diagnostic différentiel , Adolescent , Eau/effets indésirables , Urticaire/diagnostic , Urticaire/étiologieRÉSUMÉ
Cholinergic urticaria with hypohidrosis or anhidrosis (CUHA) can impair quality of life due to itching, tingling, and reduced sweating. Current treatment options for CUHA include antihistamines, pulsed steroids, and sweat-promoting therapies such as exercise or hot baths. However, the efficacy of these therapies, particularly hot bath therapy, has yet to be established. We evaluated the efficacy of hot bath therapy in patients with CUHA. We enrolled eight patients who underwent hot bath therapy between January 2010 and August 2022. Patients had a half-body bath in a bathtub filled with hot water (40-43°C) for 30-60 minutes daily for 3-7 days. After treatment, pain improved in three (42.9%) patients, urticaria improved in four (50%) patients, and anhidrosis improved in five (62.5%) patients without any severe adverse events. Because hot bath therapy is easily performed, it should be considered a treatment option for patients with CUHA.
Sujet(s)
Bains , Température élevée , Hypohidrose , Humains , Hypohidrose/thérapie , Mâle , Adulte , Femelle , Température élevée/usage thérapeutique , Adulte d'âge moyen , Urticaire/thérapie , Jeune adulte , Résultat thérapeutique , SudationRÉSUMÉ
Objective: Recent studies determined that the amoeboid form of Blastocystis acts as a factor in stimulating the host's immune responses and ultimately results in urticaria and other skin disorders. The present study was conducted in order to determine the prevalence of Blastocystis in people referred to Bushehr city health centers and the relationship of this parasite with urticaria. Methods: Fecal samples were collected from 180 males and females referred to Bushehr health centers and a questionnaire containing demographic information was completed for each person. Samples were examined by preparing direct smear (wet mount) and then formalin-detergent sedimentation techniques. Data were analyzed using SPSS 22.0 software and chi-square test. Results: The results showed that 11.1% of cases infected with Blastocystis and 55% of patients with Blastocystis had various gastrointestinal symptoms. Statistical analysis showed that there was no significant relationship between infection with some demographic factors such as sex, age, literacy level and residence, but this was significant with some clinical symptoms such as itching and urticaria. Conclusion: Despite the existence of conflicting information and many ambiguities about the Blastocystis, this emerging pathogen is very important in terms of causing allergic and skin disorders in sufferers, therefore, it is necessary that patients with urticaria be evaluated for Blastocystis along with other diagnostic procedures and physicians should request a test before any medical intervention. Thus, diagnosis and treatment of these people can play an important role in improving the health of society.
Sujet(s)
Infections à Blastocystis , Blastocystis , Fèces , Urticaire , Humains , Femelle , Mâle , Infections à Blastocystis/épidémiologie , Infections à Blastocystis/parasitologie , Adulte , Prévalence , Adulte d'âge moyen , Adolescent , Turquie/épidémiologie , Fèces/parasitologie , Urticaire/épidémiologie , Urticaire/parasitologie , Jeune adulte , Blastocystis/isolement et purification , Enfant , Sujet âgé , Enfant d'âge préscolaire , Enquêtes et questionnairesSujet(s)
Antiallergiques , Omalizumab , Urticaire , Humains , Omalizumab/usage thérapeutique , Urticaire/traitement médicamenteux , Antiallergiques/usage thérapeutique , Antiallergiques/administration et posologie , Maladie aigüe , Femelle , Mâle , Adulte , Résultat thérapeutique , Adulte d'âge moyenRÉSUMÉ
PURPOSE: The presence of wheals or hives has been viewed as a hallmark symptom of urticaria, a highly debilitating disease. This study explores our experience with omalizumab in patients with apparent mast-cell mediated pruritus in the absence of hives. MATERIALS AND METHODS: This is a retrospective case series examining all patients with mast cell-mediated pruritus in the absence of hives from April 2022 to May 2024 at a tertiary referral clinic at Icahn School of Medicine at Mount Sinai in New York. Peak pruritus-numerical rating scale (PP-NRS) itch score changes over time were recorded and analyzed. RESULTS: Six patients (67% women; mean [SD] age, 47.67 [13.52] years) were included in the analysis. The median [IQR] pruritus PP-NRS itch score before omalizumab injection was 9 [6 - 10] and the final median [IQR] PP-NRS itch score was 2.5 [0 - 5]. The mean [SD] reduction in the PP-NRS itch score was 6 [3.16]. CONCLUSIONS: This study suggests that patients with evidence of mast cell-mediated pruritus can be identified based on clinical features and may benefit from omalizumab therapy.
Sujet(s)
Mastocytes , Omalizumab , Prurit , Humains , Omalizumab/usage thérapeutique , Omalizumab/administration et posologie , Femelle , Prurit/traitement médicamenteux , Prurit/étiologie , Mâle , Adulte d'âge moyen , Études rétrospectives , Adulte , Mastocytes/effets des médicaments et des substances chimiques , Mastocytes/immunologie , Antiallergiques/usage thérapeutique , Antiallergiques/administration et posologie , Résultat thérapeutique , Indice de gravité de la maladie , Urticaire/traitement médicamenteuxRÉSUMÉ
OBJECTIVE: Fexofenadine is a second-generation inverse agonist of H1-receptor of histamine which is highly selective with proven efficacy in relieving symptoms associated with allergic conditions. It has an additional benefit of not penetrating the blood-brain barrier and therefore do not induce sedation and not impair the cognitive function/psychomotor performance. This review aimed at providing evidence based on available controlled studies to reinforce the non-sedative property of fexofenadine for treating patients with allergic rhinitis and urticaria. METHODS: We performed an electronic literature search using keywords such as fexofenadine, drowsiness, somnolence, sedation, fatigue, cognitive, impairment, psychomotor, driving performances, sleep, rapid eye movement, alertness, clinical study, in vitro study, in vivo study, and pharmacodynamics in the Embase search engine. The review included randomized controlled trials, review articles, systematic reviews, and meta-analyses, together with post-marketing analysis conducted in healthy subjects and patients with allergy and were focused on comparing the antihistaminic potential or safety of fexofenadine with other antihistamines or placebo. RESULTS: Positron emission tomography (PET) and proportional impairment ratio (PIR) data along with other objective tests from various studies confirmed the non-sedative property of fexofenadine. Results of brain H1-receptor occupancy (H1RO) obtained from PET showed no H1RO by fexofenadine, the receptor which is known to cause sedation of H1 antihistamines. Most studies calculating PIR value as 0 showed fexofenadine to be a non-impairing oral antihistamine regardless of dose. Clinical trials in adults and children showed fexofenadine to be well tolerated without sedative effect or impairment of cognitive/psychomotor function even at higher than recommended doses. CONCLUSION: Published literature based on various parameters and clinical trials conducted for evaluating the effect of fexofenadine on sedation and central nervous system shows fexofenadine is both clinically effective and non-sedating.
Sujet(s)
Antihistaminiques H1 non sédatifs , Terfénadine , Terfénadine/analogues et dérivés , Terfénadine/pharmacocinétique , Terfénadine/pharmacologie , Terfénadine/administration et posologie , Humains , Antihistaminiques H1 non sédatifs/pharmacocinétique , Antihistaminiques H1 non sédatifs/administration et posologie , Antihistaminiques H1 non sédatifs/pharmacologie , Antihistaminiques H1 non sédatifs/effets indésirables , Encéphale/effets des médicaments et des substances chimiques , Encéphale/imagerie diagnostique , Encéphale/métabolisme , Barrière hémato-encéphalique/métabolisme , Barrière hémato-encéphalique/effets des médicaments et des substances chimiques , Rhinite allergique/traitement médicamenteux , Urticaire/traitement médicamenteuxRÉSUMÉ
Chronic spontaneous urticaria (CSU) is an immunological disease that is depicted by high prevalence and eminent burden for patients and society that is attributable to the arbitrary nature of symptoms and inconsistent tools for assessment of activity and severity. Transglutaminase-2 (TG2) is a posttranslational enzyme that is pervasively expressed in many cells and tissue types including mast cells. It has various biological functions, and its role in allergic disorders has been highlighted and delineated through several postulated mechanisms. This case-control study aimed at determining the relationship between serum levels TG2 and severity of CSU. To the best of our knowledge, this is the first study in Egypt to determine the relationship between serum TG2 and severity of CSU. We enrolled 60 adult patients with confirmed diagnosis of CSU. According to urticaria activity score (UAS), patients were categorized into three groups [20 with mild disease; UAS = 0, 20 with moderate disease; UAS = 1-3, 20 with severe disease; UAS = 4-6]. Another 20 healthy individuals (age and gender matched) served as a control group. All patients were subjected to detailed medical history, clinical examination, complete blood count with differential, serum total IgE, CRP, ESR, TSH, ANA, liver and renal function tests. Serum level of TG2 was done by quantitative ELISA for all enrolled patients and controls. Serum TG2 is significantly higher in patients group compared to control group (P value < 0.001). Serum TG2 levels were significantly higher in patients with severe disease compared to patients with moderate or mild disease. This is illustrated by the significant positive correlation between serum TG2 and UAS (r 0.814 and P value 0.000). Moreover, serum TG2 accurately classified CSU patients into mild, moderate and severe subgroups: as regards differentiation between mild and moderate cases (sensitivity 70%, specificity 80%, PPV 77.8, NPV 72.7) and as for the differentiation between moderate and severe cases (sensitivity 95%, specificity 90%, PPV 90.5, NPV 94.7). Serum TG2 may have a pivotal role as a marker of severity in patients with CSU.
Sujet(s)
Marqueurs biologiques , Protein glutamine gamma glutamyltransferase-2 , Urticaire , Protein glutamine gamma glutamyltransferase-2/sang , Urticaire/sang , Urticaire/anatomopathologie , Maladie chronique , Acuité des besoins du patient , Marqueurs biologiques/sang , Humains , Mâle , Femelle , Jeune adulte , Adulte , Valeur prédictive des tests , Immunoglobuline E/sang , Protéine C-réactive/métabolisme , HémogrammeRÉSUMÉ
PURPOSE OF REVIEW: Chronic inducible urticaria (CIndU) is a group of long-persisting and challenging to manage diseases, characterized by recurrent wheals and angioedema induced by definite triggers. In this review, we address recent findings on CIndU pathogenesis, diagnosis as well as its treatment, and we discuss novel potential targets that may lead to the development of more effective therapies for CIndU patients. RECENT ADVANCES: Meaningful advances in the understanding of its pathogenesis have been reported in the last decades. Novel CIndU-specific patient-reported outcome measures enable a closer and better evaluation of patients. CIndU is a hard-to-treat disease that highly impairs quality of life (QoL) of affected patients. Provocation tests allow to diagnose CIndU subtypes. The only licensed and recommended treatment for CIndU are second generation non-sedating H1-antihistamines, which lack efficacy in many cases. Omalizumab off-label use has been assessed in all types of CIndU with overall good outcomes. Promising emerging therapies currently assessed in chronic spontaneous urticaria are paving the path for novel treatments for CIndU.
Sujet(s)
Urticaire chronique , Omalizumab , Humains , Urticaire chronique/traitement médicamenteux , Urticaire chronique/immunologie , Urticaire chronique/thérapie , Omalizumab/usage thérapeutique , Qualité de vie , Antiallergiques/usage thérapeutique , Urticaire/traitement médicamenteux , Urticaire/étiologie , Urticaire/diagnostic , Urticaire/immunologie , Urticaire/thérapieRÉSUMÉ
ABSTRACT: This article describes a teenage patient who was referred to a pediatric endocrinologist after her workup for recurring urticaria revealed a suppressed thyroid-stimulating hormone level and positive microsomal thyroid peroxidase antibodies. The patient's laboratory results revealed an autoimmune cause for the urticaria as a result of new-onset autoimmune thyroid disease.
Sujet(s)
Urticaire , Humains , Femelle , Urticaire/étiologie , Urticaire/diagnostic , Adolescent , Thyréostimuline/sang , Thyroïdite auto-immune/complications , Thyroïdite auto-immune/diagnosticSujet(s)
Urticaire chronique , Dyspnée , Granulomatose avec polyangéite , Humains , Granulomatose avec polyangéite/diagnostic , Granulomatose avec polyangéite/complications , Granulomatose avec polyangéite/traitement médicamenteux , Granulomatose avec polyangéite/anatomopathologie , Dyspnée/étiologie , Dyspnée/diagnostic , Urticaire chronique/diagnostic , Urticaire chronique/traitement médicamenteux , Femelle , Mâle , Adulte d'âge moyen , Urticaire/diagnostic , Urticaire/étiologie , Urticaire/traitement médicamenteuxRÉSUMÉ
PURPOSE OF REVIEW: Chronic spontaneous urticaria (CSU) patients sometimes do not respond to second-generation antihistamine, and 10-50% patients do not even respond to four-fold the usual dose of nonsedating H1 antihistamine, which further leads to repeated courses of oral corticosteroids to abate the symptoms. There are third-line agents approved by EAACI guidelines, which include omalizumab and cyclosporine. Certain patients are even resistant to the third-line agents. In this review, various other treatment options will be discussed in patients of refractory CSU. RECENT FINDINGS: Recently, we demonstrated azathioprine as a possible third-line option, which was found noninferior to cyclosporine in antihistamine refractory CSU. There have been trials, studies, case series and reports, which suggest other putative options for refractory CSU management. SUMMARY: Studies on the management of refractory CSU are accumulating thereby expanding the armamentarium of dermatologists and allergologist against difficult-to-treat urticaria patients.
Sujet(s)
Urticaire chronique , Ciclosporine , Omalizumab , Humains , Urticaire chronique/traitement médicamenteux , Omalizumab/usage thérapeutique , Ciclosporine/usage thérapeutique , Azathioprine/usage thérapeutique , Résistance aux substances , Immunosuppresseurs/usage thérapeutique , Antiallergiques/usage thérapeutique , Hormones corticosurrénaliennes/usage thérapeutique , Guides de bonnes pratiques cliniques comme sujet , Urticaire/traitement médicamenteuxRÉSUMÉ
To examine the prevalence of comorbidities in Chinese urticaria patients and assess medication use patterns across different ages (6-11 years, 12-17 years, above 18 years), a retrospective cohort study was performed in 192,647 urticaria patients within the Health Database. After 1:1 propensity score matching, 166,921 people were divided into the urticaria group and the control group, and the follow-up data were collected within 2 years. During the 12-month and 24-month follow-up period, significant comorbidities identified included allergic rhinitis and asthma, with distinct patterns observed across age groups. Chronic urticaria patients often have complications, such as allergic rhinitis, upper respiratory infection, oropharyngeal infection, and dental caries. The study underscores the need for age-specific treatment strategies in urticaria management.
Sujet(s)
Urticaire chronique , Comorbidité , Humains , Études rétrospectives , Enfant , Mâle , Adolescent , Femelle , Chine/épidémiologie , Prévalence , Facteurs âges , Jeune adulte , Urticaire chronique/épidémiologie , Urticaire chronique/traitement médicamenteux , Adulte , Rhinite allergique/épidémiologie , Facteurs temps , Urticaire/épidémiologie , Urticaire/diagnostic , Facteurs de risque , Score de propension , Adulte d'âge moyen , Bases de données factuelles , Asthme/épidémiologie , Asthme/traitement médicamenteux , Asthme/diagnostic , Peuples d'Asie de l'EstRÉSUMÉ
Solar urticaria is a rare idiopathic photodermatosis. According to the current knowledge its pathogenesis is most likely based on an allergic type I reaction to an autoantigen activated by ultraviolet (UV) radiation or visible light. As many of the patients suffer from severe forms of the disease, it may therefore severely impair the quality of life of those affected. In contrast, polymorphous light eruption is a very common disease, which, according to the current data, can be interpreted as a type IV allergic reaction to a photoallergen induced by UV radiation. As the skin lesions heal despite continued sun exposure, the patients' quality of life is generally not significantly impaired. These two clinically and pathogenetically very different light dermatoses have shared diagnostics by means of light provocation and an important therapeutic option (light hardening). Herein, we present an overview of the clinical picture, pathogenesis, diagnosis and available treatment options for the above-mentioned diseases.
Sujet(s)
Photodermatoses , Urticaire , Humains , Urticaire/étiologie , Urticaire/immunologie , Urticaire/diagnostic , Photodermatoses/diagnostic , Photodermatoses/étiologie , Photodermatoses/thérapie , Photodermatoses/immunologie , Lumière du soleil/effets indésirables , Rayons ultraviolets/effets indésirables , Dermatite photoallergique/diagnostic , Dermatite photoallergique/étiologie , Diagnostic différentiel , Urticaire solaireRÉSUMÉ
The term "urticaria" was first introduced by William Cullen in the eighteenth century. Urticaria is a common mast cell-mediated cutaneous disease presenting with pruritic wheals, angioedema, or both. It is classified as acute (≤6 weeks) or chronic (>6 weeks) and as spontaneous (no definite triggers) or inducible (definite and subtype-specific triggers). The international urticaria guideline on the definition, classification, diagnosis, and management of urticaria is revised every 4 years. The global network of Urticaria Centers of Reference and Excellence, the biggest and most active consortium of urticaria specialists, offers physicians and patients several research, educational, and digital care initiatives.
Sujet(s)
Urticaire , Humains , Prise en charge de la maladie , Urticaire/classification , Urticaire/diagnostic , Urticaire/thérapieSujet(s)
Vaccins contre la COVID-19 , COVID-19 , Urticaire chronique , Urticaire , Humains , Femelle , COVID-19/prévention et contrôle , Vaccins contre la COVID-19/effets indésirables , Adulte , Rappel de vaccin/effets indésirables , Mâle , Adulte d'âge moyen , SARS-CoV-2 , Vaccin BNT162/effets indésirablesRÉSUMÉ
Background: This study aimed to determine whether the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and systemic immune-inflammation index (SII) at admission affect the transition of pediatric patients diagnosed with acute spontaneous urticaria to chronic urticaria. Methods: This study included 390 patients who presented to the Department of Pediatrics at Akdeniz University Hospital with acute spontaneous urticaria between January 2020 and December 2022. A statistical comparison was made between the hematological parameters of patients who developed chronic urticaria and those who did not. Neutrophil, lymphocyte, and platelet counts, as well as NLR, PLR, and SII ratios, were used for the comparison. Results: It was observed that acute urticaria progressed to chronic urticaria in 5.8% (n = 23) of the patients. No significant differences in lymphocyte, hemoglobin, and platelet counts were observed between the group progressing to chronic urticaria and the control group (P > 0.05). However, the chronic urticaria group had higher leukocyte and absolute neutrophil counts (P = 0.009 and P < 0.001, respectively). In addition, the NLR was significantly higher in the chronic urticaria group (P = 0.029), whereas no statistically significant difference was observed in the PLR (P = 0.180). The chronic urticaria group had a significantly higher SII than the control group (P = 0.011). Conclusion: Hematological parameters, particularly NLR and SII, may be useful indicators of the transition from acute to chronic urticaria in pediatric patients. The early identification of these markers could help monitor patients and guide treatment decisions. Further comprehensive studies are required to validate these findings.
Sujet(s)
Marqueurs biologiques , Urticaire chronique , Granulocytes neutrophiles , Humains , Femelle , Urticaire chronique/sang , Urticaire chronique/diagnostic , Marqueurs biologiques/sang , Mâle , Enfant , Adolescent , Enfant d'âge préscolaire , Numération des plaquettes , Lymphocytes/immunologie , Inflammation/sang , Inflammation/diagnostic , Plaquettes , Études rétrospectives , Urticaire/sang , Urticaire/diagnostic , Urticaire/immunologie , Numération des leucocytes , Numération des lymphocytes , Évolution de la maladieRÉSUMÉ
Observational studies have reported a relationship between multiple common dermatoses and mental illness. To assess the potential bidirectional causality between 3 skin disorders (psoriasis, eczema, and urticaria) and 4 psychiatric disorders (bipolar disorder, schizophrenia, major depressive disorder, and anxiety) in the European population, we used Mendelian randomization (MR) analysis, which provides definitive evidence for causal inference. Eligible single nucleotide polymorphisms were screened for dermatological and psychiatric disorders using a genome-wide association study database. We conducted bidirectional, 2-sample MR analysis using instrumental variables related to psoriasis, eczema, and urticaria as exposure factors, and bipolar disorder, schizophrenia, major depression, and anxiety as outcomes. Reverse MR analysis with bipolar disorder, schizophrenia, major depression, and anxiety as exposure and psoriasis, eczema, and urticaria as outcomes were also performed, and the causality was analyzed using inverse-variance weighting (IVW), MR-Egger, and weighted median methods. To thoroughly assess causality, sensitivity analyses were conducted using the IVW, MR-PRESSO, and MR-Egger methods. The results showed that bipolar disorder increased the incidence of psoriasis (odds ratioâ =â 1.271, 95% confidence intervalâ =â 1.003-1.612, Pâ =â .047), heterogeneity test with Cochran Q test in the IVW showed P value > .05, (Pâ =â .302), the MR-Pleiotropy and MR-PRESSO (outlier methods) in the multiplicity test showed P value > .05, (Pâ =â .694; Pâ =â .441), and MR-Pleiotropy evidence showed no apparent intercept (interceptâ =â -0.060; SEâ =â 0.139; Pâ =â .694). Major depression increased the risk of eczema (odds ratio =â 1.002, 95% confidence intervalâ =â 1.000-1.004, Pâ =â .024), heterogeneity test showed P value > .05, (Pâ =â .328), multiplicity detection showed P value > .05, (Pâ =â .572; Pâ =â .340), and MR-Pleiotropy evidence showed no apparent intercept (interceptâ =â -0.099; SEâ =â 0.162; Pâ =â .572). Sensitivity analyses of the above results were reliable, and no heterogeneity or multiplicity was found. This study demonstrated a statistically significant causality between bipolar disorder and psoriasis, major depression, and eczema in a European population, which could provide important information for physicians in the clinical management of common skin conditions.